Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.45 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL945183 | 1.00 | SIGMAR1 (0.47) | SIGMAR1S1PR1GBA1SPHK2SPHK1 | |
| SCHEMBL1880066 | 1.00 | SIGMAR1 (0.47) | SIGMAR1S1PR1GBA1SPHK2SPHK1 | |
| Hydrochloric Acid SCHEMBL1442190 | 0.98 | SIGMAR1 (0.46) | SIGMAR1S1PR1GBA1SPHK2SPHK1 | |
| Hydrochloric Acid SCHEMBL1442192 | 0.98 | SIGMAR1 (0.46) | SIGMAR1S1PR1GBA1SPHK2SPHK1 | |
| Hydrochloric Acid SCHEMBL1730624 | 0.98 | SIGMAR1 (0.46) | SIGMAR1S1PR1GBA1SPHK2SPHK1 | |
| SCHEMBL31048186 | 0.91 | SPHK2 (0.49) | SIGMAR1GBA1SPHK2SPHK1PDK1 | |
| SCHEMBL2465869 | 0.88 | SIGMAR1 (0.54) | SIGMAR1POLB | |
| SCHEMBL2465872 | 0.88 | SIGMAR1 (0.54) | SIGMAR1POLB | |
| SCHEMBL14995124 | 0.86 | — | — | |
| SCHEMBL2459177 | 0.86 | LTA4H (0.42) | SIGMAR1GBA1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126871-B1 | TRIAZOLONE COMPOUNDS | HEPTARES THERAPEUTICS LTD (GB) | 2024-05-08 | — | — | EP | disclosed |
| US-20230146796-A1 | TRIAZOLONE COMPOUNDS | ASTRAZENECA AB (SE) | 2023-05-11 | — | — | US | disclosed |
| US-20230146796-A1 | TRIAZOLONE COMPOUNDS | ASTRAZENECA AB (SE) | 2023-05-11 | — | — | US | disclosed |
| US-20230146796-A1 | TRIAZOLONE COMPOUNDS | ASTRAZENECA AB (SE) | 2023-05-11 | — | — | US | disclosed |
| WO-2021191380-A1 | TRIAZOLONE COMPOUNDS | ASTRAZENECA AB (SE) | 2021-09-30 | — | — | WO | disclosed |
| US-8796269-B2 | Crystalline 2-(3,5-Bis(trifluoromethyl)phenyl)-N-(4-(4-fluoro-2-methylphenyl)-6-((7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)pyridin-3-yl)-N,2-dimethyl-propanamide of the formula (I), their use in therapy, and process for the preparation of the same | NERRE THERAPEUTICS LIMITED (GB) | 2014-08-05 | — | — | US | disclosed |
| US-8796269-B2 | Crystalline 2-(3,5-Bis(trifluoromethyl)phenyl)-N-(4-(4-fluoro-2-methylphenyl)-6-((7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)pyridin-3-yl)-N,2-dimethyl-propanamide of the formula (I), their use in therapy, and process for the preparation of the same | NERRE THERAPEUTICS LIMITED (GB) | 2014-08-05 | — | — | US | disclosed |
| EP-2470545-B1 | ANHYDRATE FORMS OF A PYRIDINE DERIVATIVE | NERRE THERAPEUTICS LTD (GB) | 2013-10-09 | — | — | EP | disclosed |
| EP-2170906-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2013-04-03 | — | — | EP | disclosed |
| US-8338592-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2012-12-25 | — | — | US | disclosed |
| US-20110003785-A1 | Fused Thiazole Derivatives As Kinase Inhibitors | UCB PHARMA, S.A. (BE) | 2011-01-06 | — | — | US | disclosed |
| US-20100298310-A1 | Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-11-25 | — | — | US | disclosed |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | US | disclosed |
| US-20080306060-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2008-12-11 | — | — | US | disclosed |
| EP-0972775-B1 | PYRROLOINDOLE DERIVATIVES AND INTERMEDIATES IN PRODUCING THE SAME | KYORIN SEIYAKU KK (JP) | 2004-12-08 | — | — | EP | disclosed |
| EP-1432706-A2 | 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003027085-A2 | 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| US-6080859-A | 1-CHLOROMETHYL, 3-((HETEROARYL OR ARYL)CARBONYL), 5-(HETEROCYCLE-AMINOCARBONYLOXY),7-TRIFLUOROMETHYL, 8-ALKOXYCARBONYL-1,2,3,6-TETRAHYDROPYRROLO(3,2-E)INDOLE OF GIVEN STRUCTURE; ANTITUMOR AND ANTIMICROBIAL ACTIVITY | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2000-06-27 | — | — | US | disclosed |
| EP-0972775-A1 | PYRROLOINDOLE DERIVATIVES AND INTERMEDIATES IN PRODUCING THE SAME | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2000-01-19 | — | — | EP | disclosed |
| CN-1037149-A | The preparation method of 3-alkenyl-1-azabicyclo [3,2,0] hept-2-ene\"-2-carboxylic acid cpd | FUJISAWA PHARMACEUTICAL CO (JP) | 1989-11-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003785-A1 | Fused Thiazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, MAP4K2 | SIGMAR1 3410/4885S1PR1 1949/4885GBA1 3224/4885 |
| US-20230146796-A1 | TRIAZOLONE COMPOUNDS | ADORA2A, ADORA1, ADORA3 | SIGMAR1 171/4885S1PR1 368/4885GBA1 453/4885 |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | SIGMAR1 3371/4885S1PR1 2004/4885GBA1 3485/4885 |
| US-20100298310-A1 | Thiazole Derivatives as Kinase Inhibitors | TEC, BTK, PI4KA | SIGMAR1 2470/4885S1PR1 1547/4885GBA1 2231/4885 |
| US-20080306060-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | MAP4K2, PDPK1, DAPK2 | SIGMAR1 3839/4885S1PR1 3160/4885GBA1 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.